Dotevall G, Groll E
Br Med J. 1974 Oct 5;4(5935):16-8. doi: 10.1136/bmj.4.5935.16.
The effect of a new tranquillizer, mepiprazole, in the treatment of the irritable bowel syndrome has been studied in a double-blind cross-over trial in 19 patients. After examination to exclude organic disease the patients were followed up over two treatment periods of four weeks each under either placebo or the active principle, each patient being his own control. The results indicated that the drug had a beneficial effect (P < 0.05) provided that it was given for a period of at least three weeks.
一种新型镇静剂美哌隆治疗肠易激综合征的效果在19例患者中进行了双盲交叉试验研究。在排除器质性疾病后，患者在两个为期四周的治疗期内分别接受安慰剂或活性成分治疗，每位患者均以自身作为对照。结果表明，该药物只要给药至少三周就有有益效果（P<0.05）。
